A detailed history of Walleye Capital LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Walleye Capital LLC holds 26,721 shares of BGNE stock, worth $4.75 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
26,721
Previous 2,700 889.67%
Holding current value
$4.75 Million
Previous $385,000 1458.18%
% of portfolio
0.01%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $1.67 Million - $2.61 Million
11,624 Added 77.0%
26,721 $6 Million
Q2 2024

Aug 14, 2024

BUY
$129.52 - $174.32 $1.76 Million - $2.37 Million
13,624 Added 924.92%
15,097 $2.15 Million
Q1 2024

May 15, 2024

BUY
$141.8 - $181.47 $208,871 - $267,305
1,473 New
1,473 $230,000
Q3 2023

Nov 21, 2023

BUY
$179.87 - $225.13 $1.4 Million - $1.75 Million
7,788 New
7,788 $1.4 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.4B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.